Director Gary W. Pace buys $1 million of Cardiff Oncology, Inc. (CRDF)
Gary W. Pace, director, bought $1 million of stock after a 15.8% fall. WallStPal Score 60.
Gary W. Pace, director of Cardiff Oncology, Inc., bought 687,285 shares on the open market on July 14, 2026 at an average of $1.46 a share, for a total of $1 million. The purchase was reported to the SEC on Form 4 on July 16, 2026.
It raised their holding by 51%, to 2,043,661 shares.
The purchase came after a fall: Cardiff Oncology, Inc. stock was down 15.8% over the 13 weeks before.
1 other insider also bought at least $10,000 of CRDF within 30 days, which makes this a cluster buy.
Gary W. Pace last bought CRDF on June 18, 2026.
In the 12 months up to this filing, Cardiff Oncology, Inc. insiders reported 4 open-market purchases and 0 sales.
WallStPal Score: 60 out of 100, because of raised their holding by 51%; a large purchase; 1 other insider also bought; the stock had fallen 15.8% in the 13 weeks before.
What happened next: after 1 month the stock was down 27.8% (30.2 points worse than the S&P 500). Based on weekly prices from the week of the purchase.
Source: SEC Form 4 filing ↗. This story was written automatically from the filing and weekly price data. Information, not investment advice.
Examples
Big insider purchases have made news before. In January 2016, with bank stocks falling, JPMorgan Chase CEO Jamie Dimon bought 500,000 JPMorgan shares, about $26 million of his own money, and the purchase was widely reported as a sign of confidence.
Explain it like I'm 13
Gary W. Pace helps run Cardiff Oncology, Inc.. Spending $1 million of their own money on the company's stock is like a coach buying a big stack of tickets to their own team's games: it suggests they think the team will do well. It is not a promise, and insiders can be wrong.